Hormone Replacement Therapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Therapy Type (Estrogen and Progesterone Replacement Therapy, HGH Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement Therapy, and Parathyroid Hormone Replacement), By Route of Administration (Oral, Parenteral, Transdermal, and Others) By Indication (Menopause, Hypothyroidism, Male hypogonadism, Growth hormone deficiency, and Hypoparathyroidism), and Region

Hormone replacement therapy market was valued at US$ 23,184.9 million in 2023, and is poised to grow at a CAGR of 5.3% during the forecast period (2024-2030).  The growing incidence of hormonal abnormalities, particularly in older populations, is the primary driver of the hormone replacement treatment (HRT) industry. Demand is also fueled by a greater understanding of menopause and associated health problems, such as osteoporosis. The development of customized medicine and medication delivery technologies is another factor driving market expansion. The market is restricted by safety worries about long-term HRT usage, such as the possibility of breast cancer, cardiovascular problems, and other negative consequences.

Strict regulatory oversight and rigorous approval procedures can serve as obstacles. The expanding field of natural medicines and bioidentical hormone studies provide new avenues for investigation. Growth potential can also be realized by developing emerging markets' healthcare infrastructure. The industry is experiencing a trend towards tailored HRT solutions, minimally invasive administration techniques, and more non-hormonal options to address safety corners. Digital health tools for monitoring therapy are also gaining traction.

 Key Players

The hormone replacement therapy market share is inclusive of several companies such as Novo Nordisk A/S (Denmark), Pfizer Inc. (U.S.), AbbVie’s (U.S.), Merck KGaA (Germany), Endo International plc (Ireland), Allergan plc (U.S.), Eli Lilly and Company (U.S.), Mithra Pharmaceuticals (Belgium), Amgen (U.S)

Facts and Figures

• According to information from the Menopause Center, the average cost of oral hormone replacement treatment is between US$ 130 and US$ 240 per month, or US$ 1,560 to US$ 2,440 yearly. Contrarily, injectable hormone replacement treatment ranges in price from US$ 288 to $1,440 for those with insurance and from US$ 480 to $4,800 for those without; the number of shots needed annually is between 52 and 156.

 Key Developments

• In June 2023, Pfizer Inc. relaunched DUAVEE, a menopausal hormone treatment that contains estrogen, in a better-looking package.
• In June 2022, Testosterone undecanoate, often known as Tlando, is an oral testosterone replacement medication intended for males with hypogonadism. Halozyme announced its formal introduction into the U.S. market.
• In May 2021, Myovant Sciences GmbH said that the U.S. FDA has approved its hormone therapy, Myfembree, for the treatment of uterine fibroids that cause bleeding. With an extra dosage benefit, Myovant's medication will directly compete with AbbVie.

Hormone Replacement Therapy Market Segmentation

By Therapy Type: Estrogen therapy dominates the hormone replacement therapy (HRT) market since it is widely used to treat menopausal symptoms including hot flashes and night sweats. Women who have not had a hysterectomy are frequently given estrogen either alone or in conjunction with progesterone. It is well-liked by patients and healthcare professionals due to its proven effectiveness and extensive scientific backing. Furthermore, the availability of several administration forms like tablets, gels, and patches improves patient comfort and adherence. Although men with low testosterone levels are increasingly turning to testosterone therapy, this market is still quite modest. All things considered, estrogen therapy's established advantages, safety record, and flexible delivery choices maintain its top spot in the HRT industry.

By Route of Administration: Oral administration is the most popular method in the hormone replacement therapy (HRT) market since it is convenient, simple to administer, and well-known to both patients and healthcare professionals. Because oral drugs, such as pills, are often prescribed and have simple dosage instructions, a vast population may get them. Furthermore, because oral versions are non-invasive and simple to incorporate into everyday routines, patients frequently prefer them. Although less common, alternative administration methods including transdermal patches and gels are becoming more and more well-liked due to their consistent hormone release and lower chance of gastrointestinal adverse effects. All things considered, the oral route is the most widely used way of administration in the HRT market due to its well-established history, patient choice, and wide availability.

By Indication: The primary indication for hormone replacement therapy (HRT) on the market is the control of menopausal symptoms, including hot flashes and night sweats. This frequency results from the high proportion of women going through perimenopause and menopause who also have similar symptoms, which raises the need for efficient treatment alternatives. The main prescription treatment for this indication is estrogen therapy, frequently in conjunction with progesterone. HRT's standing is reinforced by the wealth of evidence demonstrating its effectiveness in reducing menopausal symptoms and the support of medical professionals. Furthermore, the focus on menopause management has grown as a result of the increasing awareness and conversation surrounding women's health concerns. Although there are additional reasons for using HRT, such as preventing osteoporosis and treating hormone imbalances, the primary use of HRT is still for the treatment of menopausal symptoms.